This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
Join NVIDIA’s Harry Clifford and the Francis Crick Institute’s Mark Hill and James Clements as they talk through the technologies used to enable the next phase of a large prospective study of non-small cell lung cancer, TRACERx EVO. The Francis Crick Institute is a biomedical research institute working with organisations across academia, medicine, and industry to make discoveries about how life works.
The TRACERx EVO study brings together international experts from across Europe and North America, combining world-leading scientific and clinical expertise to build on the wide-reaching foundations laid by TRACERx. This ambitious programme of research has even greater data and computation requirements than the demanding first phase.